Notice: Prescription Drug List (PDL): Casirivimab and Imdevimab (COVID-19)

Notice: Prescription Drug List (PDL): Casirivimab and Imdevimab (COVID-19) The purpose of this Notice of Amendment is to notify about the addition of casirivimab and imdevimab to the Prescription Drug List (PDL) for human and veterinary use. 2023-09-30 Health Canada open-ouvert@tbs-sct.gc.ca Health and Safetynotice of amendmentPrescription Drug ListPDLcasirivimabimdevimabhuman-and-veterinary PDL Notice: Prescription Drug List (PDL): Casirivimab and Imdevimab (COVID-19)HTML https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/amendment-casirivimab-imdevimab-covid19.html Notice: Prescription Drug List (PDL): Casirivimab and Imdevimab (COVID-19)HTML https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/liste-drogues-ordonnance/avis-concernant-modifications/modification-casirivimab-imdevimab-covid19.html

The purpose of this Notice of Amendment is to notify about the addition of casirivimab and imdevimab to the Prescription Drug List (PDL) for human and veterinary use.

Data and Resources

Similar records